n.a. (ZLCS)

5.39
0.00 (0.00)
NASDAQ
Prev Close 5.39
Open 5.60
Day Low/High 5.26 / 5.60
52 Wk Low/High 3.78 / 16.90
Volume 177.07K
Exchange NASDAQ
P/E Ratio 0.34
Div & Yield N.A. (N.A)

Latest News

Why Zalicus (ZLCS) Stock Is Surging Today

Why Zalicus (ZLCS) Stock Is Surging Today

Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.

Zalicus Announces Closing Of CHTS Service Business Sale To Horizon Discovery Group

Zalicus Announces Closing Of CHTS Service Business Sale To Horizon Discovery Group

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has closed the sale of its combination High...

Zalicus Updates Progress On Z944 Clinical Development

Zalicus Updates Progress On Z944 Clinical Development

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported successful results from a phase 1 clinical study to...

Zalicus To Sell CHTS Service Business To Horizon Discovery Group

Zalicus To Sell CHTS Service Business To Horizon Discovery Group

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has entered into an agreement under which ...

Zalicus Reports Financial Results For The First Quarter 2014

Zalicus Reports Financial Results For The First Quarter 2014

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the first quarter ended March...

Zalicus Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Epirus Biopharmaceuticals

Zalicus Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Epirus Biopharmaceuticals

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Zalicus,...

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Zalicus, Inc. Over The Proposed Merger With Epirus Biopharmaceuticals, Inc.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Zalicus, Inc. Over The Proposed Merger With Epirus Biopharmaceuticals, Inc.

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc.

Why Zalicus (ZLCS) Stock Is Soaring Today

Why Zalicus (ZLCS) Stock Is Soaring Today

Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's management team led by Amit Munshi as president and CEO. Current Zalicus stockholders will own approximately 19% of the company. The merger will create a publicly-traded company listed on the NASDAQ.

Zalicus And Epirus Announce Merger Agreement

Zalicus And Epirus Announce Merger Agreement

Zalicus Inc. (Nasdaq Capital Market: ZLCS) (Zalicus), and Epirus Biopharmaceuticals, Inc.

Epirus And Zalicus Announce Merger Agreement

Epirus And Zalicus Announce Merger Agreement

Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, and Zalicus Inc.

Epirus Closes $36 Million Series B Financing

Epirus Closes $36 Million Series B Financing

Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that it has closed a $36...

Zalicus To Present At AACR 2014 Annual Meeting

Zalicus To Present At AACR 2014 Annual Meeting

Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with ...

Zalicus Reports Financial Results For The Fourth Quarter And Year-End 2013

Zalicus Reports Financial Results For The Fourth Quarter And Year-End 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ...

3 Stocks Under $10 in Breakout Territory

3 Stocks Under $10 in Breakout Territory

These under-$10 stocks are within range of triggering major breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Zalicus Plunges on Pain Drug Blowup

Zalicus Plunges on Pain Drug Blowup

Zalicus shares crashed 70% after news the company had ceased late-stage development of its experimental painkiller.

Zalicus Reports Results From Phase 2 Clinical Trials Of Z160 In Chronic Neuropathic Pain

Zalicus Reports Results From Phase 2 Clinical Trials Of Z160 In Chronic Neuropathic Pain

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies...

Zalicus Reports Financial Results For The Third Quarter 2013

Zalicus Reports Financial Results For The Third Quarter 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the third quarter ended ...

Zalicus Announces Positive Results Of Z944 Phase 1b Clinical Study In Pain

Zalicus Announces Positive Results Of Z944 Phase 1b Clinical Study In Pain

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced positive results of a Phase 1b clinical study with...

Zalicus Regains Compliance With Nasdaq Listing Requirements

Zalicus Regains Compliance With Nasdaq Listing Requirements

Zalicus Inc. (the “Company”) today announced that it has received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq...

Biotech Stock Mailbag: Bubble Debate, Cel-Sci, Zogenix, Zalicus

Biotech Stock Mailbag: Bubble Debate, Cel-Sci, Zogenix, Zalicus

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Zalicus Announces 1-for-6 Reverse Stock Split

Zalicus Announces 1-for-6 Reverse Stock Split

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of...

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Momentum traders don't understand FDA regulations.